Finance & Capital Markets

1. Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D. 3/5/2026

   On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. 

2. BoB@JPM: Post-IPO With Bolt Biotherapeutics' Drs. Randall Schatzman and Edith Perez 2/19/2023

   Bolt Biotherapeutics CEO Randall Schatzman, Ph.D. and CMO Edith Perez, M.D. are no strangers to the Business of Biotech, having previously joined us on episodes 14 and 18, respectively. The last time we spoke with Dr. Schatzman, he was preparing the company for its initial public offering. We caught up with him and Dr. Perez at the JP Morgan Healthcare Conference in San Francisco last month for a conversation on the IPO process, the impacts it's had on the go-forward plan at Bolt Bio, the company's clinical progress, and its collaboration strategy moving forward. 

3. The Implications Of China's Growing Biotech Industry With Allan Shaw 4/16/2025

   Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse.

4. Deal And Investment Trends With Investment Banker David Sans 4/2/2025

   Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted to investing over 15 years ago.

5. BoB@JPM: Rick Modi, Affinia Therapeutics 3/5/2025

   The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embracing worldview, and how that worldview contributes to his biotech leadership

6. iNK T-Cell Immuno-oncology For Solid Tumors With Dr. Ian Walters 8/30/2021

   Dr. Ian Walters' company, Portage Biotech, is focused on addressing the 75% of cancer patients who show no, or limited, response to existing therapies such as checkpoint inhibitors. Leading that charge are the company's invariant natural killer T cell agonists, designed to activate the innate and adaptive immune system, as well as a growing portfolio of proteins, antibodies, and small molecules. On this episode of the Business of Biotech, Dr. Walters shares what's fueling the company's progress, including its unique financing strategy and its approach to de-risking platform development for novel immuno-oncology therapies.

7. Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka 8/26/2026

   On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the moments when biology and execution punch back.

8. Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig 9/3/2026

   On this week's episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today’s funding environment and what it takes to build a lean virtual drug development company without institutional financing.

9. How To Be A CFO With Insmed's Sara Bonstein 4/9/2025

   On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expertise.

10. CDMO + Emerging Bio Partnership With Forge's John Maslowski And Ray's Jenny Holt 10/25/2023

    What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its contract development and manufacturing outsourcer (CDMO)? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align?